BDTX

BDTX is a clinical-stage oncology company with no approved product — the MD&A opens by calling itself 'a clinical-stage oncology company developing MasterKey therapies,' and the entire business hinges on one asset, silevertinib (BDTX-1535). That single fact reframes every headline number. The sudden swing from years of deep losses (-$126M, -$91.2M, -$82.4M, -$69.7M from FY2021–FY2024 on roughly zero revenue) to FY2025 revenue of $70.0M and net income of $22.4M is almost certainly collaboration/licensing/milestone income, not durable product sales. A clinical-stage company with a -$465M accumulated deficit and no marketed drug does not organically earn a 32% net margin. So the P/E of 4.5 and P/S of 1.4 are mirages: you cannot capitalize a one-time payment as if it recurs. Treat the 'profitability' as a one-off cash infusion, not an earnings stream.

The real story is the balance sheet and the pipeline. Cash fell 42.4% to just $21.0M while R&D — the company's actual job — was cut 34.6% to $33.6M. That combination is a warning: $21M does not fund a randomized Phase 2 GBM trial (planned to start Q2 2026) plus an ongoing NSCLC program for long. Even with FY2025 operating cash flow of $29.6M (again, collaboration-driven), the forward burn against $21M of cash points to a near-term capital raise, and raising equity at $1.75 — near the low end of a beaten-down range — is dilutive to anyone buying today. The light liabilities/equity of 0.27x is reassuring on solvency but irrelevant to the funding-gap question.